<DOC>
	<DOCNO>NCT02410239</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) mesenchymal stem cell ( IT-MSC ) patient active , advanced cerebral adrenoleukodystrophy ( cALD ) .</brief_summary>
	<brief_title>MT2014-14 IT-MSC Advanced Cerebral Adrenoleukodystrophy ( cALD )</brief_title>
	<detailed_description>This single-institution dose escalation study determine maximum tolerate dose ( MTD ) intrathecally administer allogeneic , 3rd party mesenchymal stem cell ( IT-MSC ) patient active , advanced cerebral adrenoleukodystrophy ( cALD ) .</detailed_description>
	<mesh_term>Adrenoleukodystrophy</mesh_term>
	<criteria>Age ≥ 4 year time study enrollment Diagnosis ALD diagnosis ALD make either biochemical molecular/genetic evidence ( plasma VLCFA ABCD1 mutation analysis ) supportive ALD cause cerebral demyelination Evidence active cerebral disease define presence gadolinium enhancement single brain MRI study MRI use eligibility determination may perform outside institution ; recent MRI use determine eligibility must within 2 calendar month date enrollment study ALD MRI ( Loes ) score ≥ 10 Off Nacetylcysteine , systemic immunosuppressive drug therapeutic intervention ( except hydrocortisone and/or fludracortisone treatment adrenal insufficiency ) ≥ 10 day prior first ITMSC dose Life expectancy &gt; 6 month determine enrol researcher document medical record Voluntary write consent provide parent ( ) /guardian ( ) A candidate allogeneic hematopoietic stem cell transplantation determine University Minnesota Inherited Metabolic Storage Disease group Inability undergo sedation , lumbar puncture MRI study reason Inability stay Minnesota therapy day 28 evaluation</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cerebral Adrenoleukodystrophy</keyword>
	<keyword>cALD</keyword>
</DOC>